Cargando…

Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients

Detalles Bibliográficos
Autores principales:	Fox, D, O’Connor, R, Mallon, P, McMahon, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112926/ http://dx.doi.org/10.1186/1758-2652-13-S4-P149

Ejemplares similares

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV
por: Sundell, Jesper, et al.
Publicado: (2021)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
por: Aklillu, Eleni, et al.
Publicado: (2020)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

Separating latent and acute TB
por: Doherty, T Mark
Publicado: (2010)

Comparison of Three Blood Collection Tubes for 35 Biochemical Analytes: The Becton Dickinson Barricor Tube, Serum Separating Tube, and Plasma Separating Tube
por: Shin, Sunghwan, et al.
Publicado: (2021)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
por: Huang, Sung-Hsi, et al.
Publicado: (2017)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
por: Johnston, Jenna, et al.
Publicado: (2019)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

A comparison of stability of chemical analytes in plasma from the BD Vacutainer(®) Barricor™ tube with mechanical separator versus tubes containing gel separator
por: Gawria, Ghassaan, et al.
Publicado: (2019)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
por: Sungi, Selemani Saidi, et al.
Publicado: (2018)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Efavirenz use and contraceptive methods in HIV-positive women in a large urban cohort
por: Seaton, RA, et al.
Publicado: (2010)

MicroRNA Mediated Changes in Drug Metabolism and Target Gene Expression by Efavirenz and Rifampicin In Vitro: Clinical Implications
por: Swart, Marelize, et al.
Publicado: (2019)

The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
por: Sinha, Sanjeev, et al.
Publicado: (2011)

Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients
por: Yan, Pan, et al.
Publicado: (2023)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children
por: Homkham, Nontiya, et al.
Publicado: (2019)

Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya
por: Ngayo, Musa Otieno, et al.
Publicado: (2021)

Efavirenz’ adverse reactions: a possible link between depression and gynecomastia
por: Diaconu, Ioan Alexandru, et al.
Publicado: (2014)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
por: Fonseca, Adriana Aparecida Durães, et al.
Publicado: (2020)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
por: Chamnanphon, Monpat, et al.
Publicado: (2021)

Non hepatitis jaundice - adverse reaction to rifampicin
por: Laza, Ruxandra, et al.
Publicado: (2014)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Does cost affect endotracheal tube performance?
por: Lichtenthal, P, et al.
Publicado: (2014)

Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
por: Hari, BN Vedha, et al.
Publicado: (2012)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis
por: Kendall, Emily A., et al.
Publicado: (2021)

Trends in rifampicin resistance among patients with presumptive TB in the pre-COVID and COVID-era
por: Alao, Michael Abel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jkm62kioedkpbcclskfidlcclq